lucifer
Lv21
105 积分
2022-03-17 加入
-
[Guidelines for clinical diagnosis and treatment of advanced breast cancer in China (2022 edition)]
7小时前
已完结
-
[Guidelines for clinical application of platinum drugs in breast cancer (2023 edition)]
1个月前
已完结
-
[Chinese expert consensus on the follow-up management of patients with prostate cancer receiving medical castration therapy(2024 edition)]
1个月前
已完结
-
[Guidelines for clinical application of platinum drugs in breast cancer (2023 edition)]
1个月前
已完结
-
BRCA1/2突变和同源重组修复缺陷(HRD)检测在乳腺癌中的临床研究进展
1个月前
已完结
-
The spectrum of BRCA mutations and characteristics of BRCA‐associated breast cancers in China: Screening of 2,991 patients and 1,043 controls by next‐generation sequencing
1个月前
已关闭
-
Prevalence ofBRCA1/2germline mutations in 21 401 families with breast and ovarian cancer
1个月前
已完结
-
Enhancer of Zeste Homolog 2 Inhibitor SHR2554 in Relapsed or Refractory Peripheral T-cell Lymphoma: Data from the First-in-Human Phase I Study
2个月前
已完结
-
Golidocitinib, a selective JAK1 tyrosine-kinase inhibitor, in patients with refractory or relapsed peripheral T-cell lymphoma (JACKPOT8 Part B): a single-arm, multinational, phase 2 study
2个月前
已完结
-
Golidocitinib, a selective JAK1 tyrosine-kinase inhibitor, in patients with refractory or relapsed peripheral T-cell lymphoma (JACKPOT8 Part B): a single-arm, multinational, phase 2 study
3个月前
已完结